Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Hormone Therapy Outreach Will Stress Short-Term, Low-Dose Use

Executive Summary

FDA's hormone therapy outreach campaign will initially focus on encouraging short-term, low-dose use, Commissioner McClellan told the House Agriculture Appropriations Subcommittee March 6

You may also be interested in...



FDA Hormone Therapy Education Campaign Affirms Osteoporosis Use

FDA is not taking a position on the combination of "natural" products used in conjunction with hormone therapy in its consumer education campaign on hormone therapy launched Sept. 9

Berlex Yasmin 20 NDA Filing For Lower Estrogen Dose Slated For Q4

Schering AG's Berlex subsidiary will highlight Yasmin 20's lower estrogen dose and 24-day hormone treatment regimen in marketing the oral contraceptive

Berlex Yasmin 20 NDA Filing For Lower Estrogen Dose Slated For Q4

Schering AG's Berlex subsidiary will highlight Yasmin 20's lower estrogen dose and 24-day hormone treatment regimen in marketing the oral contraceptive

Related Content

UsernamePublicRestriction

Register

PS041389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel